Business Wire

Unifrax Announces SiFAB™ Manufacturing Line

15.6.2021 14:00:00 EEST | Business Wire | Press release

Share

Unifrax, a Buffalo, New York headquartered global manufacturer of high-performance specialty materials, announced plans today to build its first large-scale SiFAB (silicon fiber anode material) manufacturing line at its north central Indiana facility that could add up to 74 new jobs by the end of 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005391/en/

SiFAB is a proprietary silicon anode battery technology which enables significantly greater energy density in lithium-ion battery systems than prevailing technologies. SiFAB is currently in advanced testing and has shown promising performance in multiple battery systems. The anode technology has successfully been tested with incremental Si loadings of greater than 40%. Along with greater energy density, SiFAB is expected to provide faster charges and longer battery life for applications including electric vehicles, portable electronics, power tools, energy grid storage and aerospace.

Unifrax is uniquely positioned to meet customer demand and develop SiFAB at scale, due to its existing manufacturing plant and infrastructure in New Carlisle. The Indiana plant will be the first to begin building SiFAB long-term manufacturing capacity. The new line is slated to create up to 20 new jobs by the end 2022, with additional growth anticipated by the end of 2023. Unifrax will have more information on open positions later this year on its website.

“SiFAB is the latest development using fiber-based technology to create step change value for customers. This transformational material represents another addition to our robust electric vehicle and battery solutions portfolio,” said John Dandolph, president and CEO, Unifrax. “Unifrax is a large, global manufacturing company introducing game changing advanced silicon anode materials that can be used in existing manufacturing processes. Our track record and proven ability to develop new and unique technologies will help transform the battery industry with SiFAB. The ability to leverage our existing facility and add new infrastructure to support SiFAB manufacturing in New Carlisle will significantly accelerate the timeline for supplying this critical material to our partners. We are appreciative of the ongoing partnership between the state of Indiana and St. Joseph County as we leverage the footprint of our existing facility to bring new jobs and opportunities to the region.”

“We designed SiFAB from its inception to be manufactured at large scale so that we could supply all market segments (EV’s, consumer electronics, power tools, and renewable storage), utilize our existing global manufacturing footprint, and deliver a product that has a high degree of quality and consistency,” said Chad Cannan, senior vice president of research and development, Unifrax.

The Indiana Economic Development Corporation offered Unifrax up to $1.1 million in conditional tax credits based on the company’s job creation plans. These tax credits are performance-based, meaning the company is eligible to claim incentives once Hoosiers are hired. St. Joseph County has also confirmed $775K in county tax incentives.

“Indiana is a leader in manufacturing, with the highest concentration of manufacturing jobs in the nation supported by 9,000 facilities across the state," said Jim Staton, interim secretary of commerce for the state of Indiana. “As new trends and technologies change the state of today’s manufacturing industry, Indiana is focused on partnering with forward-thinking companies like Unifrax to propel long-term growth in manufacturing and create quality career opportunities for Hoosiers.”

St. Joseph County Commissioner Andrew Kostielney also added, "The recent announcement by Unifrax is exciting news, not just for St. Joseph County, but for the entire region. Unifrax has long been an important manufacturing leader in the area, and this expansion indicates their commitment to our county for decades to come. Their new SiFAB line will not just create new jobs, it will also showcase the importance of green, sustainable technology."

After more than 75 years of experience in fiber-based technology and manufacturing, Unifrax is taking its first step into developing silicon fiber for the lithium-ion battery manufacturing market. With a decades-long track record of developing and supplying engineered inorganic materials at a large scale to advanced industries worldwide including electric vehicles, aerospace and chemical processing, Unifrax recently debuted two new fiber-based catalysis offerings for the automotive and industrial markets – Eco-lytic™ and FlexCat™.

To learn more about SiFAB, and to request a sample, Unifrax launched a new website introducing SiFAB with technical, manufacturing and application specific information. The new website can be found at sifab.com.

About Unifrax

Unifrax develops and manufactures high performance specialty materials used in advanced applications including high-temperature industrial insulation, electric vehicles, energy storage, filtration, and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com. For updates, follow us on Twitter, LinkedIn, and Facebook.

About Clearlake

Clearlake Capital Group, L.P. is a leading investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S. ® The firm’s core target sectors are industrials, technology and consumer. Clearlake currently has approximately $39 billion of assets under management, and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap.

About IEDC

The Indiana Economic Development Corporation (IEDC) leads the state of Indiana’s economic development efforts, helping businesses launch, grow and locate in the state. Governed by a 15-member board chaired by Governor Eric J. Holcomb, the IEDC manages many initiatives, including performance-based tax credits, workforce training grants, innovation and entrepreneurship resources, public infrastructure assistance, and talent attraction and retention efforts. For more information about the IEDC, visit www.iedc.in.gov.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Deborah L. Myers (Unifrax) – dmyers@unifrax.com or 716.812.4802
Jennifer Hurson (Clearlake Capital) – jhurson@lambert.com or 845.507.0571
Erin Sweitzer (IEDC) – 317.296.2556 or esweitzer@iedc.in.gov

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release

Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release

Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 11:00:00 EEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 11:00:00 EEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye